Cardiovascular disease remains the leading cause of death worldwide, yet our understanding of how to assess and manage risk continues to evolve.
Recently updated cholesterol guidelines from organizations like the American Heart Association and American College of Cardiology reflect a major shift: moving beyond basic cholesterol numbers and toward a more precise, individualized approach to cardiovascular risk.
At Peak Performance & Prevention (P3), this approach isn’t new—we’ve been using advanced markers and personalized strategies for years. In fact, many of the “new” recommendations have long been part of our approach and in the comprehensive lab panel.
Let’s break down what these guidelines say, what’s changed, and how it impacts your health.
What’s New in the Guidelines? Moving Beyond “Total Cholesterol”
For decades, cholesterol management focused primarily on:
- Total cholesterol
- LDL (“bad cholesterol”)
- HDL (“good cholesterol”)
While still relevant, these markers don’t tell the full story. Many people with “normal” cholesterol levels still develop heart disease, while others with elevated numbers do not.
The new guidelines emphasize risk stratification using more precise biomarkers, particularly:
- Apolipoprotein B (ApoB)
- Lipoprotein(a) [Lp(a)]
Why ApoB Is Now a Central Marker
What is Apolipoprotein B?
ApoB is a protein found on all atherogenic (plaque-forming) lipoproteins, including:
- LDL
- VLDL
- IDL
In simple terms:
👉 ApoB reflects the total number of particles capable of causing plaque buildup.
Why It Matters More Than LDL
LDL measures the amount of cholesterol, but not the number of particles. You can have:
- Normal LDL cholesterol
- But high particle count (ApoB) → higher risk
This is why ApoB is now considered one of the most accurate predictors of cardiovascular risk.
Our Approach at P3
At Peak Performance & Prevention:
- ApoB has been part of our advanced lab panels for years
- Now, ApoB is included in every lab panel moving forward
Why?
Because it provides:
- Earlier detection of risk
- More precise treatment guidance
- Better long-term prevention outcomes
Understanding Lipoprotein(a): The Genetic Risk Factor
What is Lp(a)?
Lp(a) is a genetically determined lipoprotein that increases risk for:
- Atherosclerosis
- Heart attack
- Stroke
Key Points:
- Levels are largely inherited
- Lifestyle has limited impact
- Many people have never been tested
Why the Guidelines Now Recommend It
The new recommendations suggest checking Lp(a) at least once in a lifetime, especially if:
- There’s a family history of heart disease
- You have unexplained elevated risk
Our Longstanding Practice
At P3, Lp(a) has been included in our panels because:
- It identifies hidden risk early
- It helps guide more aggressive or targeted prevention strategies
Treatment Recommendations: A Familiar Approach
While the guidelines outline stepwise treatment strategies, much of this aligns with what we’ve already been doing.
The foundation of cardiovascular health includes:
- Anti-inflammatory nutrition
- Regular movement
- Sleep optimization
- Stress management
This has always been the cornerstone of care at P3.
- Targeting ApoB (Not Just LDL)
The guidelines now emphasize lowering ApoB levels, which may include:
- Nutritional interventions
- Targeted supplementation
- Medications when appropriate
Our approach has long focused on:
- Reducing particle number (ApoB)
- Improving metabolic health
- Addressing root causes (insulin resistance, inflammation)
- Medication When Needed
For higher-risk individuals, the guidelines recommend:
- Statins
- Ezetimibe
- PCSK9 inhibitors
At P3, we:
- Use medications when appropriate and necessary
- Combine them with root-cause and lifestyle strategies
- Personalize decisions based on comprehensive risk assessment, not just a single lab value
Imaging Matters: Seeing the Plaque
Coronary Artery Calcium (CAC) Scan
The updated guidelines highlight the importance of coronary artery CT scans (CAC scoring) to:
- Detect calcified plaque
- Refine risk assessment
- Guide treatment decisions
This is a powerful tool—but it’s not the only one.
Our Alternative: CIMT Ultrasound (Coming In Office Dates)
At P3, we are excited to offer Carotid Intima-Media Thickness (CIMT) testing—an advanced, non-invasive ultrasound that evaluates:
- Early plaque formation
- Arterial thickness
- Vascular aging
Unlike CAC scans:
- No radiation exposure
- Detects earlier stages of disease
- Provides insight into arterial health over time
Upcoming CIMT Testing Dates
We are bringing CIMT testing directly to our office on:
- April 20th, 2026
- June 6th, 2026 (during our Peak Summer Event)
- July 20th, 2026
These spots are limited and tend to fill quickly.
👉 We strongly recommend scheduling now to secure your appointment.
Why This Matters: A Shift Toward Precision Prevention
The biggest takeaway from the new guidelines?
👉 We are moving from reactive care to proactive prevention.
Instead of waiting for disease:
- We identify risk earlier
- We measure more accurately
- We intervene more effectively
This is exactly what we’ve built our practice around.
How P3 Has Been Ahead of the Curve
For years, our model has included:
- Advanced lipid testing (ApoB, Lp(a))
- Advanced imaging (CIMT)
- Root-cause analysis
- Personalized treatment plans
- Early imaging strategies
Now, these approaches are becoming the standard of care.
FAQs
- Is ApoB more important than LDL?
Yes—in many cases. ApoB reflects the number of atherogenic particles, making it a more accurate predictor of cardiovascular risk than LDL alone.
- Should everyone get Lp(a) tested?
At least once, yes. Since it’s genetically determined, a single test can provide lifelong insight into your cardiovascular risk.
- If my cholesterol is normal, am I still at risk?
Possibly. Traditional cholesterol panels can miss important risk factors like elevated ApoB or Lp(a).
- What is the difference between CAC and CIMT?
- CAC measures calcified plaque in coronary arteries using a CT scan
- CIMT evaluates arterial thickness and early plaque in carotid arteries using an ultrasound
CIMT can detect changes earlier and involves no radiation.
- Do I need medication if my ApoB is high?
Not always. Treatment depends on your overall risk profile. Many patients can improve levels through lifestyle and targeted interventions, though medication is sometimes appropriate.
- Is CIMT better than a CAC scan?
They serve different purposes. CIMT is excellent for early detection and monitoring, while CAC is useful for identifying established calcified plaque.
Your Next Step
If you haven’t had advanced cardiovascular testing, now is the time.
At Peak Performance & Prevention, we offer:
- Comprehensive lab panels (including ApoB and Lp(a))
- Personalized cardiovascular risk assessments
- CIMT ultrasound testing (limited availability)
👉 Schedule your consultation today to take a proactive approach to your heart health and reserve your CIMT appointment for April 20th, June 6th, or July 20th.
Medical Disclaimer
This content is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medical care or treatment plan.
*If you are experiencing a medical emergency call 911 immediately.
